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A B S T R A C T
Purpose: Epileptic spasms (ES) beyond infancy are a highly refractory type of seizures that require the
development of an effective treatment. We therefore studied the efﬁcacy and safety of topiramate (TPM),
which is a drug that is indicated to be effective for intractable childhood epilepsy, for ES.
Methods: Out of 58 children with ES, we enrolled 33 patients treated with TPM at 12 years of age. The
administration of TPM was limited to cases of epilepsies that were resistant to any other potent
treatment. We retrospectively investigated the efﬁcacy of TPM for seizures and changes in
electroencephalogram (EEG) ﬁndings.
Results: The median age at the start of TPM treatment was 5 years, 8 months. All patients had ES and 28
also had tonic seizures. As for the efﬁcacy of TPM for all seizures, ﬁve patients became seizure-free and
two had a 50% reduction in seizures. Seizure aggravation was observed in six patients. Of 29 patients
whose EEG ﬁndings were compared before and during TPM treatment, nine showed EEG improvement
with reduced epileptic discharges. Adverse effects were observed in 13 patients and included
somnolence, anorexia, and irritability. In general, TPM was well tolerated.
Conclusions: TPM can be effective at suppressing very intractable ES in a proportion of patients who do
not respond to any other treatment. The efﬁcacy of TPM may be predictable based on EEG changes
observed early in the course of treatment. TPM is promising for the treatment of extremely intractable
childhood epilepsy and it has largely tolerable adverse effects.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Topiramate (TPM) was initially approved as adjunctive therapy
for partial-onset seizures in adults; this has been the case in Japan
since July 2007. The use of TPM is currently extended to include
childhood epilepsies in many other countries. TPM appears to be
effective for a broad range of seizure types, including generalized
seizures, particularly intractable seizures in severe epilepsies
during infancy and childhood.
Epileptic spasms (ES) are typically observed in West syndrome
(WS), a representative type of age-dependent epileptic encepha-
lopathy, but ES are occasionally observed in patients who
persistently exhibit clinical ﬁndings similar to WS beyond infancy,
and in patients with generalized epilepsies during later childhood,
including Lennox–Gastaut syndrome (LGS). ES, particularly those
occurring beyond infancy, are generally resistant to treatment.1–5* Corresponding author. Tel.: +81 86 235 7372; fax: +81 86 235 7377.
E-mail address: k_koba@md.okayama-u.ac.jp (K. Kobayashi).
1059-1311/$ – see front matter  2012 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2012.05.009There are several reports on the efﬁcacy of TPM for intractable
childhood epilepsy, including WS and LGS; the efﬁcacy rate of
50% seizure reduction has ranged from 24 to 60%.6–18 However,
the efﬁcacy of TPM for ES beyond infancy has not yet been
intensively investigated. We therefore retrospectively analyzed
the efﬁcacy and adverse effects of TPM along with the concomitant
EEG changes for children who had intractable generalized epilepsy
with ES.
2. Subjects and methods
The study subjects were patients who (1) had been visiting
Okayama University Hospital for treatment of epilepsy commenc-
ing as Ohtahara syndrome, WS, LGS, or a related disorder, (2) were
found to have ES during the period from 2008 to 2010, and (3) were
12 years of age during this period. The administration of TPM was
limited to cases of epilepsies that were resistant to any other
potent treatment. Written informed consent was obtained from
the parents of the patients, after stating that TPM was approved as
adjunctive therapy for patients with partial-onset seizures at
16 years of age in Japan. This study included subjects who werevier Ltd. All rights reserved.
Fig. 1. Age distribution of patients treated with topiramate (TPM): age at epilepsy onset (A) and age at start of TPM treatment (B).
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were undergoing trials for other drugs without usage of TPM
during the study period and patients whose parents were reluctant
about using an unapproved drug.
As for the TPM prescription, the initial dosage was 0.5–1 mg/kg.
TPM dosage was increased by 1–2 mg/kg increments every 2–
4 weeks, up to a maximum of 10 mg/kg, in accordance with a
previous study on childhood refractory epilepsy.12
The efﬁcacy of TPM was categorized as (1) excellent, when
seizures were suppressed for a period of 2 months; (2) good,
when seizure frequency was reduced by 50%; (3) minimal, when
seizures were reduced by 25–50%; (4) unchanged, when seizures
were reduced by <25% or not at all; and (5) worsened, when
seizure frequency increased. The responder rate was deﬁned as the
percentage of patients that achieved seizure freedom or 50%
seizure reduction.
We retrospectively investigated the efﬁcacy of TPM on seizures,
changes in EEG ﬁndings, and retention of TPM, as of the last
evaluation day, September 30, 2011, in children with intractable
generalized epilepsy.
Statistical analysis of the responder rate was performed with
Fisher’s exact test using SPSS (Japanese ver. 17; SPSS, Tokyo, Japan)
for age of seizure onset, diagnosis that was linked to the types of
EEG ﬁndings, and usage of representative concomitant drugs.
Values of p < 0.05 were considered signiﬁcant.
3. Results
3.1. Clinical ﬁndings of the subjects (Table 1)
There were a total of 58 candidate patients for this study (36
boys and 22 girls); 33 subjects (21 boys and 12 girls) were treated
with TPM. As for patients treated with TPM, age at the onset of
epilepsy ranged from 2 days to 8 years, 10 months, and was<2 years in 27 patients (82%) (Fig. 1A). Age at the start of TPM
treatment ranged from 6 months to 12 years, 3 months (mode: 2–
3 years) (Fig. 1B). The latency from the onset of epilepsy to the
start of TPM treatment ranged from 5 months to 12 years
(median: 3 years). Seizure frequency was daily in most patients.
All patients had ES and 28 also had tonic seizures. Mental
retardation was observed in all patients, and was particularly
severe in 28 (85%).
As for the epilepsy diagnosis and EEG ﬁndings in children
treated with TPM and children not treated with TPM, LGS, which is
characterized by the presence of multiple seizure types and/or
tonic seizures and an EEG pattern of diffuse slow spike-waves with
or without concomitant multifocal spikes, was diagnosed in 18 and
13 patients, respectively. Severe epilepsy with multifocal inde-
pendent spike foci (SE-MISF),19,20 which is characterized by the
presence of generalized seizures, including tonic seizures, and EEG
ﬁndings of dominant multifocal spikes reminiscent of hypsar-
rhythmia with or without sporadic diffuse discharges, was
observed in 9 and 10 patients in each treatment group,
respectively. WS with ES and hypsarrhythmia in EEG was
diagnosed in one patient in each treatment group; early myoclonic
encephalopathy (EME) with ES and myoclonus was diagnosed in
three patients treated with TPM; and other unspeciﬁc types of
symptomatic generalized epilepsy were diagnosed in two patients
and one patient in each treatment group, respectively.
Magnetic resonance imaging (MRI) was performed on all
patients: various degrees of brain atrophy were observed in 11
children treated with TPM and 13 not treated with TPM.
Lissencephaly was observed in one and three patients in each
treatment group, respectively; other types of cortical development
malformation in three patients in each treatment group, brain
infarction in one patient in each treatment group, tuberous
sclerosis was observed in two patients treated with TPM, and a
small unidentiﬁed white matter lesion was observed in one patient
Table 1
Demographic data of patients.
No. of patients
treated with
TPM
No. of patients
not treated
with TPM
Total 33 25
Gender
Male 21 15
Female 12 10
Etiology
Cryptogenic 2 0
Symptomatic 31 25
Perinatal complications 5 6
Cortical dysplasia 4 5
Tuberous sclerosis 2 0
Encephalitis/encephalopathy 3 4
Infarction 1 1
Multiple anomalies 2 0
Unknown 14 9
Diagnosis
EME 3 0
West syndrome 1 1
Lennox–Gastaut syndrome 18 13
SE-MISF 9 10
Symptomatic generalized epilepsy 2 1
Seizure frequency
Daily 30 21
Weekly 3 4
Seizure type
Epileptic spasms 33 25
Tonic seizures 28 22
Mental retardation
Mild 2 0
Moderate 3 1
Severe 28 24
Age at the onset of epilepsy 0–106 mo
(median: 6)
0–90 mo
(median: 5)
Age at the start of TPM treatment 6–147 mo
(median: 68)
–
Latency from epilepsy onset to
TPM treatment
5–144 mo
(median: 38)
–
Number of previous AEDs 4–12 (mean: 6) 3–12 (mean: 5)
Number of concomitant AEDs 1–5 (mean: 3) –
AEDs, antiepileptic drugs; EME, early myoclonic encephalopathy; SE-MISF, severe
epilepsy with multifocal independent spike foci.
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remaining 15 and 4 patients, respectively.
The number of antiepileptic drugs (AEDs) used before TMP
administration ranged from four to 12 (mean: 6). The number of
concomitant drugs at the start of TPM administration ranged from
one to ﬁve (mean: 3). Concomitant drugs included sodium
valproate (VPA) (used in 26 patients), zonisamide (ZNS) (20
patients), lamotrigine (LTG) (13 patients), and clobazam (CLB) (17
patients). Before TPM, synthetic adrenocorticotropic hormone
(ACTH) therapy was performed in 21 patients, oral steroid therapy
in four, thyrotropin-releasing hormone (TRH) therapy in two, and
ketogenic diet therapy in two.
3.2. Efﬁcacy of TPM
The efﬁcacy of TPM for all seizures was excellent in ﬁve patients
(15%), good in two (6%), minimal in three (9%), unchanged in 17
(52%), and worsened in the remaining six (18%) (overall responder
rate: 21%, 7 of 33 patients). Of the ﬁve patients with excellent
responses, two experienced relapse of ES after 2 or 3 months of
seizure freedom, but seizures continued to be completely
suppressed in the remaining three patients as of the last follow-
up (i.e., seizure freedom for 10 months, 1 year and 1 month, and
1 year, 6 months). In terms of the efﬁcacy of TPM according to
seizure type, the responder rate was 21% (7 of 33 patients) for ES,and 29% (8 of 28) for tonic seizures (Table 2), with no apparent
difference between seizure types.
The seizure aggravation observed in six patients was related to
ES in one patient and tonic seizures in the other ﬁve.
3.3. EEG ﬁndings during TPM treatment
EEG ﬁndings before and during the TPM treatment were
compared in 29 patients, excluding four who had to stop TPM early
without EEG recording because of adverse effects. We observed
EEG improvement with reduced epileptic discharges in 9 patients
(31%), no improvement in 17 (59%), and worsening in the
remaining 3 (10%).
Of the nine patients with EEG improvement, TPM efﬁcacy was
excellent in ﬁve, good in one, minimal in one, and unchanged in the
remaining two. In the EEGs of the three patients with persistent
seizure freedom, the epileptic discharges disappeared. The two
patients with seizure relapse after temporary freedom had
transient EEG improvement with reduction of spikes and slow
waves during the period of seizure suppression.
Of the three patients with EEG worsening, the TPM treatment
caused aggravation of seizures in two and had no effect in the
other.
The relationships between TPM effects on seizures and EEG
ﬁndings are presented in Table 3.
The clinical and EEG ﬁndings of three patients (Patients 1–3)
with seizure freedom and marked EEG improvement are presented
below. As for Patient 2, who had symptomatic LGS, EEG recorded at
3 years of age before the start of TPM showed multifocal epileptic
discharges over a slow background comprising theta and delta
waves during wakefulness, and a persistent mixture of diffuse slow
spike-waves and multifocal discharges during sleep (Fig. 2A). On
the ﬁfth day of TPM administration, when seizure reduction was
not yet apparent, some improvement in the EEG pattern was
observed, with a decrease in slow waves and epileptic discharges
during wakefulness (Fig. 2B). On the 13th day of TPM treatment,
when tonic seizures were suppressed but ES remained, EEG
showed occipital rhythmic activity with a further reduction in slow
waves during wakefulness and a reduction in diffuse epileptic
discharges during sleep as well (Fig. 2C). On the 19th day of TPM
treatment, when seizures were ﬁnally suppressed with a dose of
7.5 mg/kg, EEG no longer showed epileptic discharges (Fig. 2D).
With respect to Patient 3 with symptomatic SE-MISF, EEG
recorded at 5 years, 8 months of age before the start of TPM
showed numerous epileptic discharges over a slow background
without occipital rhythms during wakefulness, and even more
multifocal epileptic discharges during sleep. EEG showed a
reduction in epileptic discharges during both wakefulness and
sleep on the fourth day of TPM treatment, and seizures began to
decrease 3 days later. On the 15th day of TPM treatment, when
seizures were ﬁnally suppressed with a dosage of 2 mg/kg, EEG
showed occipital 7 Hz theta rhythms and no epileptic discharges
during wakefulness, and a considerable reduction in epileptic
discharges during sleep. Later examination revealed that epileptic
discharges in sleep EEGs ﬁnally disappeared after 6 months of TPM
administration.
As for Patient 1, who had symptomatic LGS, EEG recorded at
3 years, 3 months of age before the start of TPM treatment showed
multifocal spikes over a slow background without occipital
rhythms during wakefulness, and intense generalized epileptic
discharges including slow spike-waves during sleep. The frequency
of tonic seizures began to decrease after about 3 months of TPM
administration, and both tonic seizures and ES disappeared
1 month later at a dosage of 6 mg/kg. EEG then showed occipital
8 Hz alpha rhythms during wakefulness and rare central spike-
waves during sleep.
Table 2
TPM efﬁcacy.
No. of patients Excellent Good Minimal Unchanged Worsened
Seizure type
All seizures 33 5 2 3 17 6
Epileptic spasms 33 5 2 2 23 1
Tonic seizures 28 5 3 2 13 5
Age of seizure onseta
Neonatal period 2 0 0 0 1 1
Infancy 18 3 1 0 13 1
1–2 yr 7 1 0 2 1 3
2–4 yr 4 1 1 0 1 1
8–10 yr 2 0 0 1 1 0
Diagnosisb
EME 3 0 0 0 2 1
West syndrome 1 1 0 0 0 0
LGS 18 3 1 3 8 3
SE-MISF 9 1 1 0 6 1
Symptomatic GE 2 0 0 0 1 1
Seizure frequency
Daily 30 4 2 4 15 6
Weekly 3 1 0 0 2 0
EEG ﬁndings
Hypsarrhythmia 6 1 0 0 4 1
Multifocal SWsc 9 1 1 0 5 2
Diffuse slow SWs 18 3 1 3 8 3
Drugsd
VPA 26 3 2 2 13 6
ZNS 20 3 2 1 11 3
CLB 17 2 2 0 9 4
LTG 13 3 1 1 6 2
Miscellaneouse 32 4 0 2 20 6
EME, early myoclonic encephalopathy; LGS, Lennox–Gastaut syndrome; symptomatic GE, symptomatic generalized epilepsy; SE-MISF, severe epilepsy with multifocal
independent spike foci; SWs, spike-waves; VPA, sodium valproate; ZNS zonisamide; CLB, clobazam; LTG, lamotrigine. Responders are deﬁned as patients who had excellent or
good responses with 50% seizure reduction, and its relation with each of the following items is indicated below.
a Age of seizure onset was categorized as whether neonate/infancy (<12 months) or later childhood (1 year) (p = 1.000). There were no patients who had an onset of
epilepsy between 4 and 8 years of age.
b Diagnosis was categorized as whether LGS with slow spike-waves or otherwise (p = 1.000).
c Multifocal SWs with or without concomitant diffuse discharges.
d With respect to the usage of concomitant drugs, p = 0.623 (VPA), p = 0.676 (ZNS), p = 1.000 (CLB), and p = 0.393 (LTG).
e Miscellaneous drugs include clonazepam (used in a total of 7 patients), phenobarbital (6), vitamin B6 (5), phenytoin (4), carbamazepine (3), ethosuximide (3), sulthiame
(2), potassium bromide (1), and nitrazepam (1).
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The detailed ﬁndings of seven patients who responded to TPM are
summarized in Table 4. All patients had both ES and tonic seizures
and at least four AEDs were tried in all patients before TPM. Synthetic
ACTH therapy was also performed in ﬁve patients. TPM dosage at the
time of seizure suppression varied and ranged from 3 to 9 mg/kg; it
was 4 mg/kg in three patients. The three patients with long-lasting
seizure freedom (Patients 1–3) also exhibited mental improvement
following seizure termination, manifested as an ability to smile and
to provide better responses to various stimuli. Patient 5, who had a
seizure relapse, also exhibited some developmental improvement
during the temporary seizure freedom.
3.5. TPM retention
TPM was discontinued at the time of follow-up in 17 patients,
including six with seizure aggravation whose TPM dosage at theTable 3
Relationships between TPM effects on seizures and EEG ﬁndings.
Seizures EEG ﬁndings
Improved Unchanged Worsened Not recorded
Excellent 5
Good 1 1
Minimal 1 2
Unchanged 2 11 1 3
Worsened 3 2 1time of seizure aggravation was relatively low: 1 mg/kg in two
patients, 2–3 mg/kg in two patients, 4 mg/kg in one patient, and
8 mg/kg in the remaining patient. The reasons for TPM discontin-
uation were the adverse effects (mentioned below) in seven
patients and ineffectiveness in four patients.
Sixteen patients continued taking TPM, with the maximum
dosage ranging from 1.7 to 10 mg/kg (mean: 7.3 mg/kg). Duration
of TPM administration ranged from 3.4 to 36.2 months (mean:
17.6 months).
3.6. Adverse effects
Adverse effects caused by TPM were observed in 13 of 33 patients
(39%), namely, anorexia in eight, somnolence in ﬁve, irritability in
ﬁve, and hypotonia/inactiveness in three, with overlaps. No patient
showed abnormalities in liver or renal function. The maximum TPM
dosage in the 13 patients with adverse effects ranged from 1 to
9.3 mg/kg (mean: 5.1 mg/kg). In the seven patients who stopped
TPM because of adverse effects, the mean dosage was 3.2 mg/kg,
which was not high. Adverse effects were relatively severe in three
patients: two with anorexia resulting in weight loss and the other
with somnolence and hypotonia causing glossoptosis and dyspnea.
The TPM dosage of these patients ranged from 1 to 3 mg/kg. Three of
the remaining four patients experienced adverse effects at a small
TPM dosage ranging from 2 to 3 mg/kg. In patients who had adverse
effects at a small TPM dosage and showed little or no amelioration of
seizures, increasing the dosage was problematic and TPM treatment
was inevitably discontinued.
Fig. 2. Evolutional changes of EEGs in Patient 2 with TPM response. EEGs recorded during wakefulness are arranged at the top, with EEGs during sleep at the bottom. The EEG
recorded at 3 years of age before the start of TPM shows a mixture of diffuse and multifocal discharges over a slow background during wakefulness and intensiﬁcation of
discharges during sleep (A). The EEG recorded on the ﬁfth day of TPM administration with a dose of 3.8 mg/kg shows a reduction in slow waves in the background as well as a
reduction in discharges during wakefulness (B). The EEG recorded on the 13th day of TPM treatment with a dose of 7.5 mg/kg shows further improvement with the
appearance of 8 Hz occipital rhythmical activity during wakefulness (C). The EEG recorded on the 19th day of TPM treatment with a dose of 9 mg/kg showed no epileptic
discharges during either wakefulness or sleep, when seizures were ﬁnally suppressed (D).
Table 4
Proﬁles of seven TPM responders.
Patient Diagnosis Mental
retardation
Age at
onset of
epilepsy
Age at start
of TPM
Number
of AEDs
before
TPM
Special
treatment
before TPM
Efﬁcacy of
TPM
TPM dosage
at suppression
of Sz (mg/kg)
Maximum
TPM dosage
(mg/kg)
EEG effect Adverse
effect
1 Symptomatic LGS Severe 5 mo 3 yr, 3 mo 6 ACTH,
g-globulin,
ketogenic
diet
Sz-free 6 6 Improved Anorexia
2 Symptomatic LGS Moderate 1 yr, 4 mo 3 yr, 1 mo 6 ACTH Sz-free 9 9 Improved Anorexia
3 Symptomatic
SE-MISF
Severe 3 yr, 11 mo 5 yr, 8 mo 5 None Sz-free 3 3 Improved None
4 Symptomatic WS Severe 3 mo 9 mo 4 ACTH Sz-free for
2 mo,
subsequent
relapse
3 9 Temporarily
improved
None
5 Symptomatic LGS Severe 6 mo 5 yr, 5 mo 7 ACTH Sz-free for
3 mo,
subsequent
relapse
4 9 Temporarily
improved
Anorexia
6 Symptomatic
SE-MISF
Severe 1 mo 6 yr, 6 mo 6 ACTH, oral
steroid
50%
reduction
2 Improved None
7 Cryptogenic LGS Moderate 2 yr, 4 mo 6 yr, 10 mo 5 None 50%
reduction
10 No changes None
Sz, seizure; LGS, Lennox–Gastaut syndrome; SE-MISF, severe epilepsy with multifocal independent spike foci; WS, West syndrome; ACTH, synthetic adrenocorticotropic
hormone.
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None of the statistical analysis results regarding the relation-
ship between the responder rate and the various items were
signiﬁcant (Table 2). The age of seizure onset was categorized aseither neonate/infancy (<12 months in 20 patients) or later
childhood (1 year in 13 patients) p = 1.000. Diagnosis was
categorized as either LGS with slow spike-waves (18 patients)
or otherwise (15 patients) p = 1.000. Seizure frequency was daily in
30 patients and weekly in the remaining 3, p = 1.000. With respect
F. Endoh et al. / Seizure 21 (2012) 522–528 527to the effects of representative concomitant drugs, p = 0.623 for
VPA, p = 0.676 for ZNS, p = 1.000 for CLB, and p = 0.393 for LTG.
Signiﬁcant relationships could not be found through logistic
regression analysis either (see Supplementary Table 1).
4. Discussion
In the current study, generalized epilepsy with ES appeared to
be essentially intractable. The TPM responder rate was 21% (21%
for ES, 29% for tonic seizures) and therefore lower than that in
previous reports, including LGS and WS. As for LGS, Sachdeo et al.6
reported rates of 50% seizure reduction as 28 and 33% for drop
attacks and major seizures, respectively, in a double-blind placebo-
controlled study. There are other reports of open-label studies, and
the rate of 50% seizure reduction was 40–50% in most studies,
though it was as low as 13 and 25% in some studies.7,9,10,12,14 The
TPM responder rate for WS was 70–88% in some studies8,15,16 and
tended to be better than that for LGS. The contrast in the responder
rate between WS and generalized epilepsy with ES in the current
study illustrates the considerable difference between these two
disorders even though they share similar clinical ﬁndings of ES. ES
beyond infancy are observed in patients with generalized
epilepsies, including LGS, SE-MISF, and unsuppressed WS with a
protracted clinical course. ES persisting beyond infancy are a
unique type of seizures and may not be the same as ES in most
infants with WS. It has been suggested that a subset of older
children with ES actually have focal cortical-onset seizures21; such
mechanisms may complicate the pathophysiology and make the
treatment in ES beyond infancy difﬁcult. The majority of the
patients in our study underwent ACTH therapy to no avail, and an
average of six drugs had already been tried before the TPM
treatment, with limited usefulness. Therefore, the low efﬁcacy of
TPM in these patients was to be expected. The neurological and
mental prognosis of children with ES is grim.1–4 Of the current 33
patients, 31 had symptomatic epilepsy and all were mentally
retarded (severely in 85%).
In this so-far unreported research on TPM treatment for
children with generalized epilepsy with ES beyond infancy who did
not respond to any prior conventional AEDs or ACTH therapy, it is
noteworthy that TPM was effective in 21% of all patients. It is of
particular note that it provided seizure suppression for 2 months
in 15% of all patients. Three children have been enjoying seizure
freedom for approximately 1 year, with some developmental
improvement in responsiveness to various stimuli. It is expected
that the suppression of seizures and the amelioration of EEG
abnormalities that TPM treatment provides may contribute to
enhanced neurocognitive development.
Reports that include EEG ﬁndings related to TPM treatment
remain rare8,16,17; they mainly provide observations concerning
the disappearance or persistence of epileptic discharges in
responders but offer no detailed information regarding EEG
changes during the treatment. In the present EEG study involving
29 patients (88%) of a 33-patient cohort, with comparison before
and during TPM treatment, EEG improvement was observed in
nine patients, including six responders in seizures. In two dramatic
responders, EEG improvement preceded the clinical improvement
of seizure reduction; EEG improvement was ﬁrst observed during
wakefulness with a decrease in not only epileptic discharges but
also slow waves in the background. We previously investigated the
efﬁcacy of LTG in childhood epilepsy and found that EEG scarcely
improved even in LTG responders, and that the disappearance of
epileptic discharges in EEGs was not observed in any of the
patients.22 Thus, the close relation between changes in seizure
frequency and EEG ﬁndings was remarkable in TPM treatment but
lacking in LTG treatment. EEG may therefore serve as a prognostic
indicator in TPM treatment.Seizure aggravation is occasionally observed in patients
undergoing TPM treatment despite its generally positive effect
on intractable epilepsy. This was the case in six patients (18%) in
the current study—a rate similar to the 10–21% observed in other
reports.9,10,12,14,18 Types of seizures aggravated by TPM were not
described in detail in other reports, but ﬁve out of six cases of
aggravation in the current study related to tonic seizures,
suggesting that they may be more easily aggravated by TPM than
ES.
Of the 13 patients that suffered adverse effects, such as
anorexia, the effects were severe in 3 patients and mild in the
remaining 10. This distribution was comparable to that indicated
in previous reports. However, the emergence of adverse effects as a
consequence of low-dose TPM (1–3 mg/kg) was problematic
because such situations impeded subsequent titration to achieve
sufﬁcient beneﬁcial effect and resulted in early discontinuation of
TPM treatment.
Our ﬁndings lead us to conclude that TPM is effective and well
tolerated in children with intractable generalized epilepsy with ES,
and that some patients can even expect to achieve seizure freedom.
Although ES beyond infancy are extremely resistant to treatment,
TPM may be a useful treatment option for children who continue to
suffer from ES. TPM may exert its effect on intractable epilepsy
through multiple mechanisms of action.23 We were unable to
identify any particular group of patients who may beneﬁt more
from TPM with statistical signiﬁcance, but the effectiveness of TPM
may be gauged by monitoring early EEG changes during TPM
administration. The current study has inherent limitations due to
the small number of subjects and a lack of control groups. In the
future, we intend to extend the usage of TPM to more children with
intractable epilepsy, particularly ES, in order to conﬁrm its efﬁcacy.
Conﬂict of interest statement
The authors have no conﬂict of interest to disclose.
Funding sources
This study is supported in part by the Health and Labour
Sciences Research Grant: Research on catastrophic epilepsy in
infancy and early childhood – epidemiology, diagnosis and
treatment guide, in part by a Research Grant (21B-5) for Nervous
and Mental Disorders from the Ministry of Health, Labour and
Welfare, Japan, and in part by a Research Grant (19A-6) for Nervous
and Mental Disorders from the Ministry of Health, Labour and
Welfare, Japan.
Acknowledgement
We thank Professor Toshihide Tsuda of the Department of
Environmental Medicine, Epidemiology, Okayama University,
Okayama, Japan, for his important suggestions for statistical
analysis.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.seizure.2012.05.009
References
1. Talwar D, Baldwin MA, Hutzler R, Griesemer DA. Epileptic spasms in older
children: persistence beyond infancy. Epilepsia 1995;36:151–5.
2. Ohtsuka Y, Kobayashi K, Ogino T, Oka E. Spasms in clusters in epilepsies other
than typical West syndrome. Brain and Development 2001;23:473–81.
3. de Menezes MA, Rho JM. Clinical and electrographic features of epileptic spasms
persisting beyond the second year of life. Epilepsia 2002;43:623–30.
F. Endoh et al. / Seizure 21 (2012) 522–5285284. Goldstein J, Slomski J. Epileptic spasms: a variety of etiologies and associated
syndromes. Journal of Child Neurology 2008;23:407–14.
5. Auvin S, Lamblin MD, Pandit F, Valle´e L, Bouvet-Mourcia A. Infantile epileptic
encephalopathy with late-onset spasms: report of 19 patients. Epilepsia
2010;51:1290–6.
6. Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G. A double-blind,
randomized trial of topiramate in Lennox–Gastaut syndrome. Topiramate YL
Study Group. Neurology 1999;52:1882–7.
7. Glauser TA, Levisohn PM, Ritter F, Sachdeo RC. Topiramate in Lennox–Gastaut
syndrome: open-label treatment of patients completing a randomized con-
trolled trial. Topiramate YL Study Group. Epilepsia 2000;41:S81–90.
8. Glauser TA, Clark PO, McGee K. Long-term response to topiramate in patients
with West syndrome. Epilepsia 2000;41:S91–4.
9. Coppola G, Caliendo G, Veggiotti P, Romeo A, Tortorella G, De Marco P, et al.
Topiramate as add-on drug in children, adolescents and young adults with
Lennox–Gastaut syndrome: an Italian multicentric study. Epilepsy Research
2002;51:147–53.
10. Mikaeloff Y, de Saint-Martin A, Mancini J, Peudenier S, Pedespan JM, Valle´e L,
et al. Topiramate: efﬁcacy and tolerability in children according to epilepsy
syndromes. Epilepsy Research 2003;53:225–32.
11. Watemberg N, Goldberg-Stern H, Ben-Zeev B, Berger I, Straussberg R, Kivity S,
et al. Clinical experience with open-label topiramate use in infants younger
than 2 years of age. Journal of Child Neurology 2003;18:258–62.
12. Al Ajlouni S, Shorman A, Daund AS. The efﬁcacy and side effects of topiramate
on refractory epilepsy in infants and young children: a multi-center clinical
trial. Seizure 2005;14:459–63.
13. Grosso S, Galimberti D, Farnetani MA, Cioni M, Mostardini R, Vivarelli R, et al.
Efﬁcacy and safety of topiramate in infants according to epilepsy syndromes.
Seizure 2005;14:183–9.14. Grosso S, Franzoni E, Iannetti P, Incorpora G, Cardinali C, Toldo I, et al. Efﬁcacy
and safety of topiramate in refractory epilepsy of childhood: long-term follow-
up study. Journal of Child Neurology 2005;20:893–7.
15. Valencia I, Fons C, Kothare SV, Khurana DS, Yum S, Hardison HH, et al. Efﬁcacy
and tolerability of topiramate in children younger than 2 years old. Journal of
Child Neurology 2005;20:667–9.
16. Kwon YS, Jun YH, Hong YJ, Son BK. Topiramate monotherapy in infantile spasm.
Yonsei Medical Journal 2006;47:498–504.
17. Korinthenberg R, Schreiner A. Topiramate in children with west syndrome: a
retrospective multicenter evaluation of 100 patients. Journal of Child Neurology
2007;22:302–6.
18. Kluger G, Scha¨uble B, Rettig K, Schreiner A, Holthausen H. Effectiveness of low
dose of topiramate following rapid titration in multiply handicapped children
and difﬁcult-to-treat epilepsy. Neuropediatrics 2009;40:61–5.
19. Ohtahara S, Ohtsuka Y, Kobayashi K. Lennox–Gastaut syndrome: a new vista.
Psychiatry and Clinical Neurosciences 1995;49:S179–83.
20. Yamatogi Y, Ohtahara S. Multiple independent spike foci and epilepsy, with
special reference to a new epileptic syndrome of ‘‘severe epilepsy with multiple
independent spike foci’’. Epilepsy Research 2006;70:S96–104.
21. Ramachandrannair R, Ochi A, Imai K, Beniﬂa M, Akiyama T, Holowka S, et al.
Epileptic spasms in older pediatric patients: MEG and ictal high-frequency
oscillations suggest focal-onset seizures in a subset of epileptic spasms. Epilepsy
Research 2008;78:216–24.
22. Watanabe K, Kobayashi K, Endoh F, Yoshinaga H, Ohtsuka Y. Lamotrigine add-
on therapy for childhood-onset refractory epilepsy: comparison of efﬁcacy
between 3 months and 6 months after initiation. No to Hattatsu 2011;43:453–8
[in Japanese].
23. Bourgeois B. Pharmacokinetics and pharmacodynamics of topiramate. Journal
of Child Neurology 2000;15:S27–30.
